Aclaris Therapeutics, Inc. (ACRS)
6.01
-0.15
(-2.44%)
USD |
NASDAQ |
Aug 28, 16:00
6.015
0.00 (0.00%)
After-Hours: 20:00
Aclaris Therapeutics Free Cash Flow : -61.34M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -61.34M |
| March 31, 2026 | -51.45M |
| December 31, 2025 | -47.22M |
| September 30, 2025 | -79.65M |
| June 30, 2025 | -46.70M |
| March 31, 2025 | -48.99M |
| December 31, 2024 | -56.01M |
| September 30, 2024 | -18.46M |
| June 30, 2024 | -65.10M |
| March 31, 2024 | -73.68M |
| December 31, 2023 | -79.63M |
| September 30, 2023 | -91.65M |
| June 30, 2023 | -74.98M |
| March 31, 2023 | -73.94M |
| December 31, 2022 | -68.17M |
| September 30, 2022 | -66.23M |
| June 30, 2022 | -68.92M |
| March 31, 2022 | -61.34M |
| December 31, 2021 | -52.44M |
| September 30, 2021 | -44.03M |
| Date | Value |
|---|---|
| June 30, 2021 | -45.82M |
| March 31, 2021 | -44.39M |
| December 31, 2020 | -39.09M |
| September 30, 2020 | -50.88M |
| June 30, 2020 | -62.60M |
| March 31, 2020 | -73.38M |
| December 31, 2019 | -98.06M |
| September 30, 2019 | -171.92M |
| June 30, 2019 | -178.16M |
| March 31, 2019 | -178.72M |
| December 31, 2018 | -169.29M |
| September 30, 2018 | -93.56M |
| June 30, 2018 | -77.13M |
| March 31, 2018 | -65.21M |
| December 31, 2017 | -55.90M |
| September 30, 2017 | -45.24M |
| June 30, 2017 | -41.23M |
| March 31, 2017 | -40.76M |
| December 31, 2016 | -34.84M |
| September 30, 2016 | -30.97M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Corcept Therapeutics, Inc. | 106.92M |
| Nektar Therapeutics | -234.03M |
| Xeris Biopharma Holdings, Inc. | 55.67M |
| Crinetics Pharmaceuticals, Inc. | -425.18M |
| Alumis, Inc. | -351.80M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -19.85M |
| Cash from Investing (Quarterly) | 10.26M |
| Cash from Financing (Quarterly) | 0.091M |
| Free Cash Flow Per Share (Quarterly) | -0.1395 |
| Free Cash Flow to Equity (Quarterly) | -19.77M |
| Free Cash Flow to Firm (Quarterly) | -19.90M |
| Free Cash Flow Yield | -7.90% |